Immunocompromised Pneumonia



Fig. 24.1
Chest X-ray



A329322_1_En_24_Fig2_HTML.gif


Fig. 24.2
High-resolution CT scan



Question

Should the patient’s antimicrobial regimen be changed? What diagnostic test should be performed?


Answer

The patient’s antimicrobial regimen should be expanded empirically to cover Pneumocystis jirovecii (e.g. trimethoprim-sulfamethoxazole) given (1) his risk factors (cyclosporine and corticosteroids), (2) his consistent CT scan (interstitial infiltrate with cystic changes), (3) his hypoxemia disproportionate to radiographic infiltrate, (4) his lack of clinical response to an empiric regimen adequate for community-acquired pneumonia, and (5) the fact that empiric therapy does not compromise the diagnostic yield of subsequent bronchoscopy in the diagnosis of Pneumocystis pneumonia [1]. A lower respiratory tract specimen should be acquired, via bronchoscopy or mini- bronchoalveolar lavage (BAL); lavage fluid should be tested for gram stain and culture, respiratory virus polymerase chain reaction (PCR), fungal culture, galactomannan, acid-fast stain and culture, and Pneumocystis PCR.

The patient underwent flexible bronchoscopy, and a positive Pneumocystis PCR assay confirmed the diagnosis. The patient received intravenous trimethoprim-sulfamethoxazole, and oxygenation gradually improved over the next 5 days. The patient was ultimately extubated and recovered full lung function. After 21 days of treatment, the patient’s trimethoprim-sulfamethoxazole was changed to the prophylactic dose (1 double-strength tablet [160/800] once daily) for the duration of his immunosuppression.



Principles of Management



Presentation


Pneumonia is a common and morbid complication of immunosuppression, whether due to primary immunodeficiency or, more commonly, secondary to a systemic disease process or its treatment. The presentation of pneumonia among immunosuppressed patients is often more subtle, indolent and atypical than among immunocompetent patients [2]; the same immune deficits that permit microbial reproduction in the lower respiratory tract can decrease the intensity of fever, sputum production, or radiographic infiltrates. Immunosuppressed patients are often vulnerable to competing or concurrent non-infectious lung processes such as cardiogenic edema (e.g. among patients receiving cardiotoxic chemotherapy or aggressive hydration with chemotherapeutic regimens), medication toxicity (e.g. among patients receiving bleomycin or methotrexate), radiation pneumonitis, or malignancy (e.g. Kaposi’s Sarcoma among patients with Human Immunodeficiency Virus [HIV]/Acquired Immunodeficiency Syndrome [AIDS]).


Etiology


The presence and persistence of microbes in the respiratory tract are determined by the balance of microbial immigration, elimination and local microbial growth conditions [3, 4], all of which are altered in immunosuppressed patients. The microbiota of the upper respiratory tract (the primary source community for migration of microbes to the lungs [4, 5]) are altered by systemic immunosuppression, whether by underlying disease (e.g. HIV/AIDS) [6] or immune-suppressing medications [7]. Impairment of innate and adaptive immunity decreases the elimination rate of transient microbes, increasing the likelihood of persistent reproduction, and makes the microbial growth conditions of the lung environment more hospitable to dysregulated reproduction [3]. Each patient’s specific constellation of immune deficits predisposes him/her to a select number of opportunistic pathogens (Table 24.1). Consideration of each patient’s candidate pathogen profile is critical to the appropriate selection of empiric antimicrobial therapy. Despite the wide breadth of potential pathogens in this population, the most common culprits remain the bacteria and viruses responsible for community-acquired pneumonia (e.g. Streptococcus pneumoniae) [9], which should be covered by any empiric regimen. Coverage for atypical organisms (Mycoplasma spp., L. pneumophila and C. pneumoniae) is warranted in community-dwelling patients until a specific pathogen is identified.


Table 24.1
Correspondence of immunodeficiency and susceptibility to respiratory pathogens





































Immune defect

Disease examples

Iatrogenic examples

Organisms to suspect

Innate immunity

Neutrophil abundance

Leukemia

Parvovirus infection

Agranulocytosis

Chemotherapy

Methotrexate

Clozapine

Gram-negative bacilli

Staphylococcus spp.

Fungi (e.g. Aspergillus spp.)

Neutrophil function

Chronic granulomatous disease

Cirrhosis

Uremia

Anti-TNF agents [8]

Staphylococcus aureus

Fungi (e.g. Aspergillus spp.)

Adaptive immunity

T-cell abundance and function

HIV/AIDS

Lymphoma

Primary immunodeficiency

Chemotherapy

Corticosteroids

Calcineurin inhibitors

Anti-T-cell antibodies

Pneumocystis jirovecci

Cryptococcus spp.

Intracellular bacteria (e.g. Legionella spp.)

M. tuberculosis

Viruses (CMV, HSV, VZV)

B-cell abundance and function

Multiple myeloma

Primary immunodeficiency

Rituxumab

Encapsulated bacteria: S. pneumoniae, H. influenzae


Diagnosis


Chest x-rays are of notoriously poor sensitivity in identifying pneumonia among immunocompromised patients; in one large series, the majority of neutropenic patients with infiltrates on thin-sliced CT scans had no detectable abnormality on chest radiograph [10]. High-resolution CT scan is often helpful for confirming the presence of infection, guiding site selection for bronchoalveolar lavage, and directing empiric therapy based on imaging characteristics. The presence of cavitation is associated with Mycobacterium spp., Nocardia spp., Aspergillus spp. and P. jirovecci.; interstitial infiltrates suggest viral (e.g. Cytomegalovirus [CMV]) pneumonia or Pneumocystis; dense consolidation implies either bacterial pathogens or Aspergillus spp.. Serologic tests are of decreased utility in immunocompromised patients, especially in patients with impaired T-cell and B-cell immunity (Table 24.1), whereas antigen-based testing (e.g. Streptococcus and Legionella urinary antigens, Cryptococcus serum antigen testing) can be useful. An aggressive approach to sampling the lower respiratory tract (via bronchoscopy or miniature bronchoalveolar lavage [“mini-BAL”]) is warranted, as the spectrum of potential pathogens usually exceeds any reasonable empiric antimicrobial regimen. Depending on the patient’s degree and type of immunosuppression, lower respiratory tract specimens should be tested for gram stain and bacterial culture, fungal culture, acid fast stain and culture, respiratory viral PCR, CMV antigen, galactomannan, Pneumocystis PCR. Recommended diagnostic tests by specimen site are listed in Table 24.2.


Table 24.2
Diagnostic testing in immunocompromised patients with suspected pneumonia






























Specimen

Diagnostic tests

Bronchoalveolar lavage fluid

Cell count and differential

Gram stain and bacterial culture

Fungal stain and culture

Acid-fast bacteria stain and culture

Respiratory virus PCR

Pneumocystis jirovecci PCR

CMV antigen

Galactomannan

Serum

Bacterial culture

Only gold members can continue reading. Log In or Register to continue

Stay updated, free articles. Join our Telegram channel

Jul 20, 2017 | Posted by in Uncategorized | Comments Off on Immunocompromised Pneumonia

Full access? Get Clinical Tree

Get Clinical Tree app for offline access